Trial Profile
Quality of life in second-line treatment of metastatic renal cell carcinoma with Everolimus : EVERPRO
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Feb 2019
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms EVERPRO
- 19 Jan 2019 Results evaluating the quality of life in second-line treatment of metastatic renal cell carcinoma with everolimus published in the Oncology Research and Treatment
- 15 Mar 2018 New trial record
- 10 Feb 2018 Results presented at the 2018 Genitourinary Cancers Symposium.